A district court in Baltimore Sept. 5 ruled against drug companies and PhRMA, denying their attempt to obtain a preliminary injunction against 340B pricing for contract pharmacy arrangements in Maryland, according to Reuters. The AHA filed amicus briefs defending Maryland’s law against this drug industry challenge July 29 and Aug. 2, in addition to similar briefs filed in Missouri Aug. 29 and West Virginia Aug. 16.
 

Related News Articles

Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.“It is a ‘solution’ in search of a…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA Aug. 7 filed an amicus brief in the Supreme Court in defense of states’ affidavit of merit requirements in federal court, which require plaintiffs to…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…